Sotatercept

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence found in previous trials, according to a press release.

Healio Pulmonology has compiled the top news from the FDA posted in 2024.

Adults with pulmonary arterial hypertension functional class three or four faced a decreased risk for all-cause mortality or morbidity events with Winrevair vs. placebo, according to phase 3 ZENITH trial topline results.

The FDA has approved sotatercept, an activin signaling inhibitor, for treating adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.

When added to background therapy for pulmonary arterial hypertension, sotatercept improves 6-minute walk distance and WHO functional class vs. placebo, according to an evidence report by the Institute for Clinical and Economic Review.

The 2023 European Respiratory Society International Congress featured lectures and groundbreaking research on a wide variety of respiratory diseases/conditions.

The FDA has granted priority review to sotatercept, a novel activin signaling inhibitor designed to treat adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.

Patients with pulmonary arterial hypertension receiving sotatercept, a novel activin signaling inhibitor, plus background therapy are expected to live longer, according to a European Respiratory Society International Congress presentation.

Safety and efficacy of sotatercept (Acceleron Pharma/Merck) vs. placebo at 24 weeks in adults with PAH.

NEW ORLEANS — Sotatercept, a novel activin signaling inhibitor, reduced risk for death and clinical worsening by 84% in patients with pulmonary arterial hypertension compared with placebo, according to results of the STELLAR trial.